{"id":146470,"date":"2026-04-17T13:02:37","date_gmt":"2026-04-17T17:02:37","guid":{"rendered":"https:\/\/medcitynews.com\/?p=146470"},"modified":"2026-04-22T17:25:48","modified_gmt":"2026-04-22T21:25:48","slug":"kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/","title":{"rendered":"Kailera\u2019s Upsized IPO Brings In $625M for Pipeline of Injectable &amp; Oral Obesity Drugs"},"content":{"rendered":"<p>Kailera Therapeutics believes it can stand out in a crowded and competitive market for obesity medicines. Global clinical trials underway could help build the case for differentiation, and the company now has $625 million in IPO cash to support its pipeline of injectable and oral drugs through key data readouts.<\/p>\n<p>Investors are apparently persuaded by Kailera\u2019s prospects. Strong investor interest enabled Kailera to boost the deal size by adding nearly six million more shares than it initially planned to offer. Late Thursday, the Waltham, Massachusetts-based company <a href=\"https:\/\/www.globenewswire.com\/news-release\/2026\/04\/16\/3275907\/0\/en\/Kailera-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html\" target=\"_blank\" rel=\"noopener\">priced 39 million shares at $16 each<\/a>, which was the top of the price range it set in <a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/2096997\/000119312526151904\/d113532ds1a.htm\" target=\"_blank\" rel=\"noopener\">preliminary financial terms<\/a>. Kailera\u2019s shares will trade on the Nasdaq under the stock symbol \u201cKLRA.\u201d<\/p>\n<p>The most advanced Kailera program is ribupatide, a peptide engineered to activate the GLP-1 and GIP receptors. Those are the same targets as <a href=\"https:\/\/medcitynews.com\/2023\/11\/fda-approval-eli-lilly-weight-loss-obesity-zepbound\/\" target=\"_blank\" rel=\"noopener\">Eli Lilly\u2019s Zepbound<\/a>, but Kailera contends its once-weekly injectable drug has greater binding affinity to its targets and a longer half-life that enables better drug exposure in the body through the full weekly dosing period. Three global Phase 3 tests of ribupatide are underway; preliminary data expected in 2028.<\/p>\n<p>Kailera is also developing an oral version of ribupatide, KAI-9531. The oral obesity market is growing quickly following <a href=\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-oral-glp-1-fda-approval-foundayo-orforglipron-obesity-weight-loss-lly\/\" target=\"_blank\" rel=\"noopener\">FDA approvals for daily pills from Eli Lilly<\/a> and Novo Nordisk, both designed to activate the GLP-1 receptor. In addition to hitting two targets, Kailera contends its pill can stand apart with better tolerability. In the filing, Kailera said global Phase 3 tests of oral ribupatide could begin in the first half of 2027.<\/p>\n<p>Competitive weight loss with better tolerability are also goals for KAI-7535, Kailera\u2019s GLP-1 receptor-targeting pill. Like Lilly\u2019s Foundayo, KAI-7535 is an oral small molecule that does not have the <a href=\"https:\/\/medcitynews.com\/2025\/12\/novo-nordisk-wegovy-pill-fda-approved-oral-glp-1-drug-obesity-weight-loss-nvo\/\" target=\"_blank\" rel=\"noopener\">same dosing restrictions as Novo Nordisk\u2019s Wegovy pill, an oral peptide<\/a>. Kailera said preliminary results from a Phase 2 test of its oral GLP-1 drug are expected in 2027. By developing both injectable and oral obesity drugs, Kailera said it can address a broader range of patients, including those with high body mass indexes (BMIs) that require medication with a stronger effect than what\u2019s offered by currently available products.<\/p>\n<p>\u201cWe believe that injectable treatments will remain foundational for patients needing significant weight reduction,\u201d Kailera said in the filing. \u201cMeanwhile, for patients with a lower BMI, lower incidences of gastrointestinal side effects may be needed to achieve optimal weight loss and treatment persistence, and we believe oral treatments can unlock adoption for those with more modest weight loss needs, while also supporting the chronic treatment journey of those living with higher BMIs.\u201d<\/p>\n<p>Kailera\u2019s IPO comes less than two years after the biotech <a href=\"https:\/\/medcitynews.com\/2024\/10\/metabolism-kailera-therapeutics-weight-loss-obesity-drugs-glp1-gip-hengrui-china\/\" target=\"_blank\" rel=\"noopener\">launched with four in-licensed metabolic disorder drugs supported by $400 million<\/a> in Series A financing. Last October, <a href=\"https:\/\/medcitynews.com\/2025\/10\/kailera-therapeutics-obesity-drug-weight-loss-glp-1-gip-metabolic-disorder\/\" target=\"_blank\" rel=\"noopener\">Kailera closed a $600 million Series B round<\/a>.<\/p>\n<p>In the IPO filing, Kailera reported its cash and marketable securities totaled $652 million as of the end of 2025. That capital combined with the IPO proceeds will support clinical development of the pipeline: $625 million for global Phase 3 tests of injectable ribupatide; $150 million to advance oral ribupatide to Phase 3; and $50 million to take GLP-1 pill KAI-7535 through the completion of a planned Phase 2 study. Kailera said it expects its capital will last into the second quarter of 2028.<\/p>\n<p><strong>Alamar\u2019s IPO Will Finance Its Plans in Proteomics<\/strong><\/p>\n<p>Alamar Biosciences <a href=\"https:\/\/www.globenewswire.com\/news-release\/2026\/04\/17\/3275924\/0\/en\/Alamar-Biosciences-Announces-Pricing-of-Upsized-Initial-Public-Offering.html\" target=\"_blank\" rel=\"noopener\">raised $191.3 million<\/a> to grow the company, a maker and seller of instruments used in proteomics, the large-scale analysis of entire sets of proteins. The company\u2019s products are based on a proprietary technology called Nucleic Acid Linked Immuno-Sandwich Assay, or NULISA for short. Alamar\u2019s customers include universities, biopharmaceutical companies, and contract research organizations.<\/p>\n<p>Fremont, California-based Alamar claims NULISA improves the signal-to-noise ratio compared to other proteomics technologies. Competitors include Quanterix and <a href=\"https:\/\/medcitynews.com\/2023\/10\/thermo-fisher-adds-proteomics-to-its-portfolio-through-3-1b-olink-acquisition\/\" target=\"_blank\" rel=\"noopener\">Olink, a Thermo Fisher Scientific subsidiary<\/a>. The $74.2 million in revenue Alamar reported for 2025 is nearly triple the company\u2019s revenue for the prior year. But Alamar is not yet profitable, posting a $29.8 million net loss last year.<\/p>\n<p>\u201cWe expect that our losses will continue in the near term as we continue to invest significantly in research and development to enhance our NULISA technology, expand our NULISA assay menu and enhance our software offerings, expand our manufacturing capabilities, and build out our commercialization team and footprint,\u201d Alamar said in its <a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/2104204\/000119312526158122\/d39680ds1a.htm\" target=\"_blank\" rel=\"noopener\">IPO filing<\/a>.<\/p>\n<p>Alamar offered 11.25 million shares at $17 apiece, which was the top end of the $15 to $17 price range the company set in preliminary IPO terms. The company\u2019s shares will trade on the Nasdaq under the stock symbol \u201cALMR.\u201d<\/p>\n<p><strong>More Biotechs Join the IPO Queue<\/strong><\/p>\n<p>Two more clinical-stage biotech companies revealed their plans to join the public markets. Seaport Therapeutics and Hemab Therapeutics recently filed IPO paperwork with the Securities and Exchange Commission.<\/p>\n<p>Boston-based <a href=\"https:\/\/medcitynews.com\/2024\/04\/puretech-health-startup-seaport-therapeutics-depression-lymphatic-system-drug-delivery\/\" target=\"_blank\" rel=\"noopener\">Seaport spun out of PureTech Health in 2024<\/a> with a platform technology that leverages the lymphatic system to make more of a drug\u2019s active pharmaceutical ingredient available in the body to provide a therapeutic effect. Lead drug candidate SPT-300 is in Phase 2b testing for major depressive disorder; preliminary data are expected in the first half of 2027, according to <a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/2042347\/000119312526151211\/d73463ds1.htm\" target=\"_blank\" rel=\"noopener\">the filing<\/a>. Seaport has applied for a Nasdaq listing under the stock symbol \u201cSPTX.\u201d<\/p>\n<p>Meanwhile, Hemab Therapeutics is eyeing a public listing to support its pipeline of drugs for blood clotting disorders. The Cambridge, Massachusetts-based company\u2019s lead program is <a href=\"https:\/\/medcitynews.com\/2023\/02\/blood-clotting-biotech-hemab-hauls-in-135m-to-drug-rare-bleeding-disorders\/\" target=\"_blank\" rel=\"noopener\">sutacimig (formerly HMB-001), a bispecific antibody currently in Phase 1\/2 development for prophylactic treatment of Glanzmann thrombasthenia<\/a>, a rare inherited disorder affecting platelets. Hemab expects to begin Phase 3 testing in this indication in the second half of the year, according to <a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/2114044\/000119312526151378\/d50309ds1.htm\" target=\"_blank\" rel=\"noopener\">the filing<\/a>. Sutacimig is also in Phase 2 testing for prophylactic treatment of deficiency of the clotting protein Factor VII. Hemab has applied for a Nasdaq listing under the stock symbol \u201cCOAG.\u201d<\/p>\n<p><em>Photo by Getty Images<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kailera Therapeutics\u2019 IPO proceeds will support global clinical trials for its obesity drug candidates. Meanwhile, proteomics company Alamar Biosciences upsized its own IPO while clinical-stage biotechs Seaport Therapeutics and Hemab Therapeutics joined the IPO queue. <\/p>\n","protected":false},"author":25932,"featured_media":11322,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"featured_image_focal_point":[],"homepage_placement":"top","homepage_placements":{"top":true,"featured":true,"sidebar":false},"homepage_alternative_layout":false,"featured_categories":[54,69],"hide_from_feed":false,"footnotes":""},"categories":[69,54],"tags":[53562,34071,12102,49456,7758,52131,5172,12867],"class_list":["post-146470","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-pharma-channel","tag-alamar-biosciences","tag-biotech-ipo","tag-clinical-trials","tag-glp-1-drugs","tag-investing","tag-kailera-therapeutics","tag-obesity-treatment","tag-weight-loss"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kailera\u2019s Upsized IPO Brings In $625M for Pipeline of Injectable &amp; Oral Obesity Drugs - MedCity News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kailera\u2019s Upsized IPO Brings In $625M for Pipeline of Injectable &amp; Oral Obesity Drugs - MedCity News\" \/>\n<meta property=\"og:description\" content=\"Kailera Therapeutics\u2019 IPO proceeds will support global clinical trials for its obesity drug candidates. Meanwhile, proteomics company Alamar Biosciences upsized its own IPO while clinical-stage biotechs Seaport Therapeutics and Hemab Therapeutics joined the IPO queue.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity News\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T17:02:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-22T21:25:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/11\/GettyImages-1222725177.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"744\" \/>\n\t<meta property=\"og:image:height\" content=\"470\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank Vinluan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@frankvinluan\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank Vinluan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/\"},\"author\":{\"name\":\"Frank Vinluan\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"headline\":\"Kailera\u2019s Upsized IPO Brings In $625M for Pipeline of Injectable &amp; Oral Obesity Drugs\",\"datePublished\":\"2026-04-17T17:02:37+00:00\",\"dateModified\":\"2026-04-22T21:25:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/\"},\"wordCount\":975,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/11\/GettyImages-1222725177.jpg\",\"keywords\":[\"Alamar Biosciences\",\"biotech IPO\",\"Clinical Trials\",\"GLP-1 drugs\",\"investing\",\"Kailera Therapeutics\",\"Obesity\",\"weight loss\"],\"articleSection\":[\"BioPharma\",\"Pharma\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/\",\"url\":\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/\",\"name\":\"Kailera\u2019s Upsized IPO Brings In $625M for Pipeline of Injectable &amp; Oral Obesity Drugs - MedCity News\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/11\/GettyImages-1222725177.jpg\",\"datePublished\":\"2026-04-17T17:02:37+00:00\",\"dateModified\":\"2026-04-22T21:25:48+00:00\",\"author\":{\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"breadcrumb\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#primaryimage\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/11\/GettyImages-1222725177.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/11\/GettyImages-1222725177.jpg\",\"width\":744,\"height\":470},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medcitynews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kailera\u2019s Upsized IPO Brings In $625M for Pipeline of Injectable &amp; Oral Obesity Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medcitynews.com\/#website\",\"url\":\"https:\/\/medcitynews.com\/\",\"name\":\"MedCity News\",\"description\":\"Healthcare technology news, life science current events\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medcitynews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\",\"name\":\"Frank Vinluan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"caption\":\"Frank Vinluan\"},\"description\":\"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/frankvinluan\/\",\"https:\/\/x.com\/frankvinluan\"],\"url\":\"https:\/\/medcitynews.com\/author\/fvinluan\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kailera\u2019s Upsized IPO Brings In $625M for Pipeline of Injectable &amp; Oral Obesity Drugs - MedCity News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/","og_locale":"en_US","og_type":"article","og_title":"Kailera\u2019s Upsized IPO Brings In $625M for Pipeline of Injectable &amp; Oral Obesity Drugs - MedCity News","og_description":"Kailera Therapeutics\u2019 IPO proceeds will support global clinical trials for its obesity drug candidates. Meanwhile, proteomics company Alamar Biosciences upsized its own IPO while clinical-stage biotechs Seaport Therapeutics and Hemab Therapeutics joined the IPO queue.","og_url":"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/","og_site_name":"MedCity News","article_published_time":"2026-04-17T17:02:37+00:00","article_modified_time":"2026-04-22T21:25:48+00:00","og_image":[{"width":744,"height":470,"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/11\/GettyImages-1222725177.jpg","type":"image\/jpeg"}],"author":"Frank Vinluan","twitter_card":"summary_large_image","twitter_creator":"@frankvinluan","twitter_misc":{"Written by":"Frank Vinluan","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#article","isPartOf":{"@id":"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/"},"author":{"name":"Frank Vinluan","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"headline":"Kailera\u2019s Upsized IPO Brings In $625M for Pipeline of Injectable &amp; Oral Obesity Drugs","datePublished":"2026-04-17T17:02:37+00:00","dateModified":"2026-04-22T21:25:48+00:00","mainEntityOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/"},"wordCount":975,"commentCount":0,"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/11\/GettyImages-1222725177.jpg","keywords":["Alamar Biosciences","biotech IPO","Clinical Trials","GLP-1 drugs","investing","Kailera Therapeutics","Obesity","weight loss"],"articleSection":["BioPharma","Pharma"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/","url":"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/","name":"Kailera\u2019s Upsized IPO Brings In $625M for Pipeline of Injectable &amp; Oral Obesity Drugs - MedCity News","isPartOf":{"@id":"https:\/\/medcitynews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#primaryimage"},"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/11\/GettyImages-1222725177.jpg","datePublished":"2026-04-17T17:02:37+00:00","dateModified":"2026-04-22T21:25:48+00:00","author":{"@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"breadcrumb":{"@id":"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#primaryimage","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/11\/GettyImages-1222725177.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/11\/GettyImages-1222725177.jpg","width":744,"height":470},{"@type":"BreadcrumbList","@id":"https:\/\/medcitynews.com\/2026\/04\/kailera-ipo-glp1-gip-ribupatide-obesity-drug-injectable-oral-weight-loss-klra\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medcitynews.com\/"},{"@type":"ListItem","position":2,"name":"Kailera\u2019s Upsized IPO Brings In $625M for Pipeline of Injectable &amp; Oral Obesity Drugs"}]},{"@type":"WebSite","@id":"https:\/\/medcitynews.com\/#website","url":"https:\/\/medcitynews.com\/","name":"MedCity News","description":"Healthcare technology news, life science current events","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medcitynews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35","name":"Frank Vinluan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/image\/","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","caption":"Frank Vinluan"},"description":"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan","sameAs":["https:\/\/www.linkedin.com\/in\/frankvinluan\/","https:\/\/x.com\/frankvinluan"],"url":"https:\/\/medcitynews.com\/author\/fvinluan\/"}]}},"_links":{"self":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/users\/25932"}],"replies":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/comments?post=146470"}],"version-history":[{"count":3,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146470\/revisions"}],"predecessor-version":[{"id":146538,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146470\/revisions\/146538"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media\/11322"}],"wp:attachment":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media?parent=146470"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/categories?post=146470"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/tags?post=146470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}